In the first quarter, Johnson & Johnson’s medtech sales reached $8.02 billion, marking a 2.5% year-over-year increase, despite facing a $400 million charge due to U.S. tariffs. The cardiovascular sector saw significant growth at 16.4%, while orthopedics experienced a 4.2% decline. CFO Joe Wolk noted that the financial impact stems mainly from tariffs on products shipped to China. While the company has limited price leverage due to existing contracts, its performance suggests resilience in a challenging economic environment, potentially signaling similar challenges for other device manufacturers.

Source: https://www.supplychaindive.com/news/jnj-tariff-costs-400-million-2025/745635/